T1	Participants 61 103	malignant pleural and pericardial effusion
T2	Participants 260 286	control group, 30 patients
T3	Participants 338 362	N-CWS group, 26 patients
T4	Participants 404 475	55 patients with malignant pleural effusion due to primary lung cancer.
